QVIMM Trademark

Trademark Overview


On Wednesday, January 26, 2022, a trademark application was filed for QVIMM with the United States Patent and Trademark Office. The USPTO has given the QVIMM trademark a serial number of 97240187. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The QVIMM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
qvimm

General Information


Serial Number97240187
Word MarkQVIMM
Filing DateWednesday, January 26, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, January 29, 2022NEW APPLICATION ENTERED
Tuesday, November 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 4, 2022ASSIGNED TO EXAMINER
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, August 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 31, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 31, 2023SOU EXTENSION 1 FILED
Monday, July 31, 2023SOU EXTENSION 1 GRANTED
Wednesday, January 10, 2024SOU EXTENSION 2 GRANTED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 2 FILED
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED